Picture of RTW Biotech Opportunities logo

RTWG — RTW Biotech Opportunities News Story

0.000.00%
gb flag iconLast trade - 00:00
FinancialsBalancedMid CapNeutral

Edison issues flash on RTW Venture Fund (RTW)

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221213:nRSM5432Ja&default-theme=true

RNS Number : 5432J  RTW Venture Fund Limited  13 December 2022

London, UK, 13 December 2022

 

Edison issues flash on RTW Venture Fund (RTW)

RTW Venture Fund (RTWVF) is managed by global healthcare specialist RTW
Investments (RTW). It has announced that on 7 December 2022 portfolio company
Prometheus Biosciences (NASDAQ: RXDX, cap $4.9bn) reported positive data on
two of its clinical trials. At 31 October 2022, which is the date of RTWVF's
last published NAV, Prometheus was its third-largest holding, making up c 7.5%
of the fund. This company's share price rose by 165.7% on 7 December and by a
further 22.4% on 8 December (despite the announcement of an upsized $500m
secondary offering). Prometheus is an example of RTW's long-term, full life
cycle investment approach, which supports companies ranging from newco
formation to mid-stage venture to pre-initial public offering and public
markets.

 

RTWVF, along with other funds managed by RTW, participated in a $130m
financing round in Prometheus in November 2020 and then supported the
company's IPO in March 2021.

Click here
(https://www.edisongroup.com/publication/positive-newsflow-from-major-fund-holding/31766/?utm_campaign=RNSreach%20Press%20Releases&utm_source=RNSreach&utm_medium=Press%20Release)
to view the full report or here
(https://share.hsforms.com/1WayFK-InRvqjXZI_5ifilQ3k1vq) to sign up to receive
research as it is published.

 

All reports published by Edison are available to download free of charge from
its website

www.edisongroup.com (http://www.edisongroup.com)

About Edison: Edison is a leading research and investor relations consultancy,
connecting listed companies to the widest pool of global investors. By
focusing on the volume and quality of investors reached - across institutions,
family offices, wealth managers and retail investors - Edison can create and
gauge intent to purchase, even in the darkest pools of capital, and then make
introductions via non-deal roadshows, events or virtual meetings.

Having been the first in-market 17 years ago, Edison now has more than 100
analysts covering every economic sector. Headquartered in London, Edison also
has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in
Athens, Johannesburg and Sydney.

Edison is authorised and regulated by the Financial Conduct Authority
(https://register.fca.org.uk/ShPo_FirmDetailsPage?id=001b000000MfYL6AAN) .

Edison is not an adviser or broker-dealer and does not provide investment
advice. Edison's reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

Mel Jenner +44 (0)20 3077 5700 investmenttrusts@edisongroup.com
(mailto:investmenttrusts@edisongroup.com)

Learn more at www.edisongroup.com (http://www.edisongroup.com) and connect
with Edison on:

LinkedIn        www.linkedin.com/company/edison-group-/
(http://www.linkedin.com/company/edison-group-/)

Twitter           www.twitter.com/Edison_Inv_Res
(http://www.twitter.com/Edison_Inv_Res)

YouTube       www.youtube.com/edisonitv
(http://www.youtube.com/edisonitv)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABGBDDGGBDGDX

Recent news on RTW Biotech Opportunities

See all news